Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study

BACKGROUND: In patients with relapsing–remitting multiple sclerosis (RRMS), subcutaneous (sc) interferon (IFN)β-1a and IFNβ-1b have been shown to reduce relapse rates. A formulation of IFNβ-1a has been produced without fetal bovine serum and without human serum albumin as an excipient (not currently...

Descripción completa

Detalles Bibliográficos
Autores principales: Singer, Barry, Bandari, Daniel, Cascione, Mark, LaGanke, Christopher, Huddlestone, John, Bennett, Randy, Dangond, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541262/
https://www.ncbi.nlm.nih.gov/pubmed/23216674
http://dx.doi.org/10.1186/1471-2377-12-154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541262/
https://www.ncbi.nlm.nih.gov/pubmed/23216674
http://dx.doi.org/10.1186/1471-2377-12-154

Ejemplares similares